

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 5

March 10th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association and membership news*. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- ICER ovarian cancer comments
- CMS ICD-10 website updates
- 17th *Multidisciplinary Management of Cancers: A Case-based Approach*—LATE REGISTRATION ENDS TODAY!
- ASCO QOPI Spring Round

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members. The next regular *ANCO FAX News* will be published on March 24th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The Association of Northern California Oncologists (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The *Institute for Clinical and Economic Review* (ICER) draft scoping document on treatments for ovarian cancer will be open for comments until March 27th. For more information, please visit icer-review.org/material/ovarian-cancer-draft-scope/?utm_source=Ovarian+Draft+Scope&utm_campaign=Ovarian+scope&utm_medium=email.

CMS's Medicare Quality Payment Program website is at qpp.cms.gov. The Program will implement the Merit-Based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (APM) incentive payment provisions of MACRA. For more information, go to:

- CMS's executive summary at qpp.cms.gov/docs/QPP_Executive_Summary_of_Final_Rule.pdf
- CMS's fact sheet at qpp.cms.gov/docs/Quality_Payment_Program_Overview_Fact_Sheet.pdf.
- CMS's tool for physicians to review and select the MACRA quality measures that best fit their practice at qpp.cms.gov/measures/quality
- ASCO's analysis of and comments on the final rule at www.asco.org/advocacy-policy/asco-in-action/asco-releases-analysis-macra-final-rule-and-quality-payment-program and www.asco.org/sites/new-www.asco.org/files/content-files/ASCO-2016-MACRA-Comments-Final.pdf.
- ASCO's fact sheets to help oncology practices successfully participate in the QPP at www.asco.org/macra

- ACCC's MACRA presentation at www.anco-online.org/ACCCMACRAPresentation.pdf.
- ASH's summary of the final rule at www.hematology.org/Advocacy/Policy-News/2016/6755.aspx, comments on the final rule at www.hematology.org/Advocacy/Testimony.aspx, and MACRA 101 for Hematologists at ashondemand.org/Areas/Redesign/Content/MACRA_101_11-15-16.pdf.
- Bobbi Buell's analysis of the MACRA final rule at www.anco-online.org/BBMacraFinalRule.pdf
- The *California Medical Association's* (CMA) MACRA Resource Center at www.cmanet.org/macra

Download the presentations from ASCO's webinar entitled *MACRA Rules are Final: Time to Implement* at www.asco.org/practice-guidelines/practice-management-issues/medicare-program/macra.

CMS is replacing its Road to 10 webpage and redirecting web traffic to www.cms.gov/ICD10 due to a sharp decline in web visits to the Road to 10 webpage. The www.cms.gov/ICD10 website is now the one-stop site for coders to obtain the official CMS ICD-10 resources.

CMS has extended the deadline from February 28th to March 13th for the 2016 Quality Reporting Document Architecture (QRDA) data submission for the EHR reporting mechanism.

This affects all individual eligible professionals and PQRS practices. Eligible professionals who do not satisfactorily report 2016 quality measure data to meet the PQRS requirements will be subject to a downward PQRS payment adjustment on all Medicare Part B Physician Fee Schedule services rendered in 2018. For more information, please go to www.cms.gov/medicare/quality-initiatives-patient-assessment-instruments/pqrs/analysisandpayment.html. In related news, the California *Department of Health Care Services* (DHCS) has announced that it will extend the deadline for Medi-Cal meaningful use reporting for the 2016 program year to May 2nd. After that date, DHCS will only accept 2017 attestations.

CMA, MOASC, and State Legislative & Regulatory Issues

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The March 2017 edition includes:

- Meaningful use reporting deadline pushed back two weeks to March 13
- Don't forget: Physicians must still report data for 2016 PQRS
- The Coding Corner: CPT 2017—Medicare coding and coverage updates

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Home Health Care: Proper Certification Required; Home Health Quality Reporting Program Provider Trainer-May 3 and 4; Clinical Laboratories: Report Lab Data through March 31; Hospice Quality Reporting Program: Rerun Your Quality Measure Reports
- *Claims, Pricers, and Codes*—April 2017 Average Sales Price Files
- *Available Publications*—Transitional Care Management Services Fact Sheet-Revised; HIPAA Basics for Providers: Privacy, Security, and Breach Notification Rules

Fact Sheet-Reminder; PECOS Technical Assistance Contact Information Fact Sheet-Reminder; Medicare Enrollment Resources Educational Tool-New; Chronic Care Management Services Call: Audio Recording and Transcript-New; Advance Care Planning Fact Sheet-Reminder

- ICD-10 Coding Revisions to NCDs CR9982
- Clinical Laboratory Fee Schedule-Medicare Travel Allowance Fees for Collection of Specimens CR9960
- Updated Editing of Professional Therapy Services CR9933
- Radiopharmaceutical Fee Schedule 2016 Addition & Updates-Revised
- Episode Payment Model Operations CR9916
- Updates to the Medicare Claims Processing Manual, Pub. 100-04, Chapters 12, 17, and 23 to Correct Remittance Advice Messages CR9906
- Healthcare Provider Taxonomy Codes (HPTCs) April 2017 Code Set Update CR9869
- RARC, CARC, MREP and PC Print Update CR9878

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming Noridian/JEMAC meetings/workshops include:

- Noridian Medicare Portal Functionality for Part B Providers (March 23)
- Reopenings (March 28)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

DHCS/MediCal is soliciting input from interested parties regarding the Prostate Cancer Treatment Program (PCTP) for consideration regarding the future direction of the PCTP. Responses are requested by March 15th at files.constantcontact.com/bce9d04e001/55cbd4bb-1924-481f-b5e2-72459e665fe3.pdf.

Anthem Blue Cross has announced that effective May 15th, Myriad Genetic Laboratories will no longer be an in-network laboratory provider. A

complete list of in-network participating laboratories may be obtained online at www.anthem.com/ca > Provider > Find a Doctor.

Anthem Blue Cross is implementing important changes to its national drug list (formulary) effective April 1st. Review these changes at file.anthem.com.s3-website-us-east-1.amazonaws.com/64774CAEENABC.pdf.

UnitedHealthcare's Network Bulletin (March 2017) is now available online at unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles entitled: Reviewing and Validating Provider Data; Administrative Guide Update; Credentialing Plan 2017-2018 Summary of Changes. In addition, **UnitedHealthcare's commercial reimbursement policies will begin requiring biosimilar biological products to include a modifier that identifies the manufacturer of the specific product** for dates of service on or after June 1st. Specifically, the modifier for Q5101 (filgrastim) Zarxio will be ZA (Novartis/Sandoz) and the modifier for Q5102 (infliximab) Inflectra will be ZA (Pfizer/Hospira).

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

17th Multidisciplinary Management of Cancers: A Case-based Approach LATE REGISTRATION ENDS TODAY!

The 17th Multidisciplinary Management of Cancers: A Case-based Approach returns to the Silverado Resort and Spa in Napa on March 17-19th. The meeting is sponsored by the Association of Northern California Oncologists, Stanford Cancer Institute, UC Davis Comprehensive Cancer Center, and the UCSF Helen Diller Family Comprehensive Cancer Center. Go to www.multicancers.org to register.

SAVE THE DATE ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The first Update will take place on May 6th at the Sacramento Hyatt Regency with Mehrdad Abedi, M.D., University of California, Davis, Sandy Wong,

M.D., University of California, San Francisco, and Julian Davis, M.D., University of California, Davis. The latest research on novel treatment modalities for hematologic malignancies, myeloma, and amyloidosis, along with case studies for these diagnoses will be presented. These updates are supported by Janssen Biotech, Merck, Pfizer Oncology, and Pharmacyclics. Watch for a meeting announcement in late March.

Additional Education Meetings

March 13th
9th Annual Palliative Care Summit
Coalition for Compassionate Care of California
Sacramento
(ccccsummit.org)

March 13th
An Ongoing Journey to Advance Molecular Testing in Lung Cancer
ACCC & AMP
(<https://attendee.gotowebinar.com/register/2573310585943935235>)

March 14th
Diagnostics in Small Cell Lung Cancer: How Diagnostics Help Inform Treatment Decisions—Part II of Living with Small Cell Lung Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 15th
Managing the Side Effects of Immunotherapy—Part II of Immunotherapy: A Promising New Approach to Treating Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 15th
Management of Immune-related Adverse Events in Patients with Non-Small Cell Lung Cancer
(NSCLC)
ACCC Institute for Clinical Immuno-Oncology
(<https://attendee.gotowebinar.com/register/7236769310437359617>)

March 16th
Management of Squamous Cell Carcinoma of the Lung
International Association for the Study of Lung Cancer
(www.iaslc.org/webinars/management-squamous-cell-carcinoma-lung)

March 16th
The Role of Genetics Professionals in a Community Cancer Program
ACCC & AMP

(<https://attendee.gotowebinar.com/register/2573310585943935235>)

March 16-18th

Multidisciplinary Thoracic Cancers Symposium: Bringing Precision Medicine to Thoracic Cancer Care

American Society Clinical Oncology
San Francisco

(www.thoracicsymposium.org/index.aspx)

March 23rd

Update on Glioblastoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 24th

Clinical Genetics vs Tumor Genomic Profiling: Relevance in Cancer Care

ACCC & AMP

(<https://attendee.gotowebinar.com/register/2573310585943935235>)

March 28th

Progress in the Treatment of Follicular Lymphoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 29th-31st

Cancerscape: Business & Policy, Value & Quality—ACCC 43rd Annual Meeting

Association of Community Cancer Centers
Washington, DC

(www.accc-cancer.org/meetings/AM2017.asp)

April 3rd

Advances in the Treatment of Colorectal Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 5th

Progress in the Treatment of Oral and Head and Neck Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 6th

Update on Chronic Lymphocytic Leukemia (CLL)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

April 20th-22nd

Cancer Metastasis through the Lymphovascular System: Biology & Treatment—7th International Symposium

Sentinel Node Oncology Foundation
San Francisco

(www.cancermetastasis.org)

April 27-28th

The 2017 Community Oncology Conference:

Fueling the Cancer Moonshot

Community Oncology Alliance

Washington, D.C.

(<http://www.coaconference.org>)

April 28th

The New Age of Molecular Testing and Targeted Therapies in Lung Cancer

ACCC & AMP

(<https://attendee.gotowebinar.com/register/2573310585943935235>)

May 2nd

Update on Advanced Ovarian Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 5th

Advances in the Treatment of Renal Cell Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

May 18th

Progress in the Treatment of Multiple Myeloma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for March 21st**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at

execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, Palo Alto Medical Foundation, and Valley Medical Oncology Consultants* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Dendreon • Eisai • EMD Serono • Exelixis
Foundation Medicine*

*Genoptix Medical Laboratory
GenPath Oncology • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology
Heron Therapeutics • Incyte
Infinity Pharmaceuticals
Ipsen Biopharmaceuticals
Janssen Oncology • Jazz Pharmaceuticals
Lilly Oncology • Merrimack Pharmaceuticals
Medivation • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Prometheus Laboratories, Inc.
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheranostics, EMD Serono, and Pfizer US Biosimilars* as new Corporate Members for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

Genentech Bio Oncology informs ANCO that the *United States Food and Drug Administration* has approved Tecentriq for treatment of locally advanced or metastatic urothelial carcinoma in patients with disease progression during or after platinum-containing chemotherapy or have progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapies.

Heron Therapeutics informs ANCO that NCCN has granted Sustol a Category 1 recommendation for use in patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC) and has identified Sustol as a preferred agent for preventing CINV following MEC.

Janssen Biotech is hosting an educational program entitled *Darzalex-based Triplet Therapy for Multiple Myeloma Patients at First Relapse* with Amy Marsala, M.P., *UC San Francisco*, on March 17th at *Morimoto*, 610 Main Street, Napa. RSVP at www.medforcereg.net/SOMP108529.

Clinical Trial News

Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase II Study of Epacadostat (INCB024360) with Pembrolizumab (MK-3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies. Principal Investigator: Pamela Kunz, MD; Contact: Ativ Zomet, (650) 736-0697, azomet@stanford.edu
- Randomized Phase II Study of Platinum and Etoposide vs Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas [EA2142; NCT02595424]. Principal Investigator: Pamela Kunz, MD; Contact: Martina Steffen, (650) 721-4077, steffenm@stanford.edu

Further information is available at cancer.stanford.edu/trials/.

UC Davis brings the following clinical trial (not previously listed or changed) to the attention of the ANCO membership:

- A Phase 1b Study of ABT-199 in Combination with Azacitidine or Decitabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy (M14-358/NCT02203773). Principal Investigator: Brian Jonas, M.D., Ph.D.; Contact: Sofia Milunovich, (916) 734-0167

Further information is available at www.ucdmc.ucdavis.edu/cancer/clinical_trials/.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase I Study of PEGPH20, Gemcitabine Plus Nab-Paclitaxel in Patients With Borderline Resectable Pancreatic Cancer (CC#144515). Contact: Louis Wong, (415) 514-8101, louis.wong@ucsf.edu
- A Phase Ib/II Safety and Efficacy Trial of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma (CC#144525). Contact: Maddy Griffith, (415) 353-7792, madeline.griffith@ucsf.edu
- A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy (CC#15452). Contact: Maddy Griffith, (415) 353-7792, madeline.griffith@ucsf.edu
- Phase I clinical trial of VX-970 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors (CC#169518). Contact: Phu Lam, (415) 514-6363; phu.lam@ucsf.edu
- A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors (CC#169519). Contact: Kathleen (Katie) Comerford, (415) 514-6674; kathleen.comerford@ucsf.edu

- A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-controlled study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation (CC#17451). Contact: Malori Mindo, (415) 502-6313; malori.mindo@ucsf.edu
- An open-label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin who have progressed on prior treatment (CC#17452). Contact: Bryant Chee, (415) 353-7145; bryant.chee@ucsf.edu
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma (CC#164518). Contact: Louis Wong, (415) 514-8101; loius.wong@ucsf.edu
- Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor (CC#17455). Contact: Bryant Chee, (415) 353-7145; bryant.chee@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

To better understand the contributions of advanced practice providers (APPs) working in oncology, ASCO is partnering with four other healthcare provider organizations (*Advanced Practitioner Society for Hematology and Oncology, American Academy of PAs, Association of Physician Assistants in Oncology, Oncology Nursing Society*) to conduct a survey that will examine the specific roles and responsibilities of APPs within the cancer care delivery team. Read more about the survey at www.asco.org/advocacy-policy/asco-in-action/new-survey-advanced-practice-providers-oncology-launched. If you are contacted to participate, you will receive the survey via postal mail or an e-mail from ASCO.survey@jacksonsurveys.com. ASCO urges members to complete the survey and return it as instructed by March 29th. The survey should take 20 minutes or less to complete. **ASCO's Clinical Affairs Department is dedicated to providing services, education, and resources to support oncology practices.** It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and

efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/asco-in-action/asco-s-clinical-affairs-department-opens-new-survey-practice-operations.

ASCO's 2017 Quality Training Program, a six-month course in data-driven quality improvement, will now take place in two locations—Dallas and Portland. The session dates for Portland are April 20th-21st, June 28-29th, and October 18th. To learn more about and apply to participate in the Program, visit www.asco.org/training-education/professional-development/quality-training-program.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on January 1st, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please contact Elaine Towle (elaine.towle@asco.org). Learn more about ASCO's physician payment reform efforts at www.asco.org/advocacy-policy/policies-positions-guidance/coverage-reimbursement/physician-payment-reform.

On March 14th, the Spring Round for ASCO's QOPI will open for reporting. Practices are encouraged to register now in preparation for the opening date. The Spring Round will close on May 9th. Learn more at www.asco.org/advocacy-policy/asco-in-action/qopi-spring-round-reporting-opens-march-14-register-now.

A new collaboration between ASCO and the American Board of Internal Medicine (ABIM) enables participants of ASCO's Quality Oncology Practice Initiative (QOPI) to receive Maintenance of Certification (MOC) Practice Assessment points from ABIM. For more information on ABIM MOC, eligibility and requirements, please visit university.asco.org/practice-assessment-activities.

In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting. While one measure is the minimum requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measure to become fully acquainted with the system and ensure that the CMS requirements are met.

ASH and the College of Pathologists (CAP) have published an evidence-based guideline that addressed the initial work-up of acute leukemia. Read the guideline at www.archivesofpathology.org/doi/pdf/10.5858/arpa.2016-0504-CP?code=coap-site. **See what you missed at this year's ASH Annual Meeting by visiting ASH on Demand to access more than 100 hours of recorded sessions.** Go to ashondemand.org/Meetings/Annual-Meetings for more information.

ACCC's online Oncology Drug Database provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of Financial Advocacy Network resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

ACCC's 2017 Patient Assistance and Reimbursement Guide is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile

device. The *Financial Advocacy Network* (FAN) app is available at acc-fan-app.org. **ASH also has a webpage (at www.hematology.org/Clinicians/Drugs/Programs/) that provides a consolidated list of resources for hematologists and patients trying to access high cost hematologic drugs.** And, at NCCN's Reimbursement Resource Room (www.nccn.org/reimbursement_resource_room/default.asp) **you can select a cancer diagnosis or supportive care indication and learn about reimbursement help and services available to you.** Finally, *assistPoint* is your **website for complimentary one-stop cancer Patient Assistance.** You can search by generic, brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more. **NCCN has published and/or updated their *Clinical Practice Guidelines in Oncology* and/or *Drugs & Biologics Compendium* for acute myeloid leukemia (V1.2017); anal carcinoma, systemic light chain amyloidosis, Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma (evidence blocks); chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; chemotherapy order templates); chronic myeloid leukemia, colon cancer, dermatofibrosarcoma protuberans, genetic/familial high-risk assessment: breast and ovarian, melanoma, multiple myeloma, myeloproliferative neoplasms, occult primary, rectal cancer (biomarkers compendium); Hodgkin lymphoma (V1.2017); malignant pleural mesothelioma (V1.2017); non-small cell lung cancer (V4.2017); pancreatic adenocarcinoma (V1.2017); small cell lung cancer (V3.2017); and, thymomas and thymic carcinomas (V1.2017).** Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.

The *California Dialogue on Cancer* is pleased to announce the *American Cancer Society's* forthcoming *80% by 2018 California Colorectal Cancer Roundtable* event in Sunnyvale on March 21st. This event will be an opportunity to connect with different groups that are working toward the collective goal of have 80% of the adult population aged fifty and over by 2018. For more

information, please visit starcite.smarteventcloud.com/rsvp/invitation/invitation.asp?id=/m1c9c3bc-BLI2B1R0X8Y9.

Individual Membership Dues for 2017

Second notices of membership renewal for 2017 were mailed to all members in early February. If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.

ANCO seeks new members. **All members of a practice should join ANCO.** And, ANCO seeks to enroll radiation oncologists as members, so please send us contact information for the radiation oncologists within your practice and/or to whom you refer patients.

Remember, a larger ANCO is a stronger ANCO!